Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Methodol. Jul 20, 2022; 12(4): 246-257
Published online Jul 20, 2022. doi: 10.5662/wjm.v12.i4.246
Gut microbiota interactions with anti-diabetic medications and pathogenesis of type 2 diabetes mellitus
Ravi Kant, Lakshya Chandra, Vipin Verma, Priyanshu Nain, Diego Bello, Siddharth Patel, Subash Ala, Rashmi Chandra, Mc Anto Antony
Ravi Kant, Mc Anto Antony, Department of Endocrinology, Diabetes and Metabolism, Medical University of South Carolina, Anderson, SC 29621, United States
Ravi Kant, Mc Anto Antony, Department of Endocrinology, Diabetes and Metabolism, AnMed Health, Anderson, SC 29621, United States
Lakshya Chandra, Subash Ala, Department of Internal Medicine, St Francis Hospital, Greenville, SC 29601, United States
Vipin Verma, Rashmi Chandra, Department of Internal Medicine, Medical University of South Carolina, Anderson, SC 29621, United States
Vipin Verma, Department of Internal Medicine, AnMed Health, Anderson, SC 29621, United States
Priyanshu Nain, Department of Graduate Medical Education, Maulana Azad Medical College, Delhi 110002, India
Diego Bello, Department of Surgery, AnMed Health, Anderson, SC 29621, United States
Siddharth Patel, Department of Internal Medicine, Decatur Morgan Hospital, Decatur, AL 35601, United States
Author contributions: Kant R, Chandra L and Antony MA designed the outline, performed the writing, prepared the figure and edited the paper; Verma V, Nain P, Bello D and Patel S performed the writing, and prepared the table and figure; Ala S and Chandra R provided the input in writing the paper, performed the writing and edited the paper.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ravi Kant, MD, Associate Professor, Department of Endocrinology, Diabetes and Metabolism, Medical University of South Carolina, 2000 E Greenville Street, Suite 3100, Anderson, SC 29621, United States. kant.ravi.md@gmail.com
Received: March 1, 2022
Peer-review started: March 1, 2022
First decision: April 19, 2022
Revised: May 3, 2022
Accepted: June 18, 2022
Article in press: June 18, 2022
Published online: July 20, 2022
Processing time: 141 Days and 2.8 Hours
Core Tip

Core Tip: Gut microbiota influence the pathogenesis of type 2 diabetes mellitus (T2DM) and metabolic syndrome through multiple mechanisms. The role of dysbiosis and various pathophysiological mechanisms such as altered metabolism of short-chain fatty acids, interaction with gut hormones, increased gut microbial metabolite trimethylamine-N-oxide and bacterial translocation in the pathogenesis of T2DM and cardio-metabolic diseases have been extensively studied. With increasing evidence regarding the significance of gut microbiota, it is imperative to review the role of gut microbiota in the pathogenesis of T2DM. This review also discusses the interaction between gut microbiota and the various medications used in the treatment of T2DM.